Funding for this research was provided by:
Centro de Investigación Biomédica en Red de Cáncer
Generalitat de Catalunya (PERIS SLT002/16/0037, 2017SGR1282, 2014SGR338)
Spanish Ministry of Economy and Competitiveness cofunded by FEDER funds (SAF2015-68016-R and SAF2012-33636)
Spanish Association Against Cancer (080253)
The Mexican National Council for Science and Technology (CONACyT) fellowship
Catalonia Health Department (SLT002/16/00409)
CERCA Generalitat de Catalunya
Text and Data Mining valid from 2019-11-28
Received: 23 May 2019
Accepted: 9 October 2019
First Online: 28 November 2019
: GC and JdV have received personal fees from VCN Biosciences and AstraZeneca, respectively, outside the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work. All other authors declare that they have no competing interest.
: This study was approved by the Ethics Committee of the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). <i>S</i>pecimens were obtained after the patients had provided written informed consent.
: We obtained written informed consent from the patient to publish patient’s clinical and molecular information.